Covering iPS cells, cell therapy, cardiovascular, diabetes and ophthalmology, plus Japan’s regenerative-medicine system and clinical trials.
A plain-language glossary for reading Japanese regenerative-medicine trials: jRCT, recruitment status, Phase I/II, eligibility and exclusion criteria, primary endpoints, adverse events, and conditional, time-limited approval.
Reading Japan’s iPS-based regenerative medicine through Amchepry, Heartseed HS-005 and the PMDA conditional, time-limited approval pathway — why it draws attention, and why the results still need careful interpretation.
Japan has completed the first catheter-delivered administration of iPS-derived cardiomyocyte spheroids. A look at the EMERALD trial, the difference between HS-001 and HS-005, and the wider cardiac regenerative-medicine landscape after ReHeart’s approval.
Tokushima University Hospital has completed the first TUFF-IPC autologous transplant. What type 1 diabetes involves, the limits of islet transplantation, how the adipose-derived approach works, and why this remains early-stage clinical research.
Japan has added Amchepry (raguneprocel) — the world’s first commercialized iPS cell–derived product — to public insurance at ~¥55.3 million. What the Sumitomo Pharma / Kyoto University Parkinson’s therapy is, and what its conditional approval means.
